EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease

Alexander Nasr, Tomoyuki Mizuno, Kei Irie, Jonathan R Dillman, Kimberly Jackson, Kimberly Lynch, Alexa Horrell, Thomas Aviles, Kelly Chun, Jane Yang, Brendan Boyle, Jeffrey S Hyams und 3 weitere

Clinical Pharmacokinetics · 2026

DOI: 10.1007/s40262-026-01685-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Alexander Nasr und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, MLC 2010, 3333 Burnet Avenue, Cincin…. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Adalimumab, Tumor Necrosis Factor-alpha. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Division of Diabetes, Endocrinology, and Metabolic Diseases, Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Personalizing anti-tumor necrosis factor (TNF) therapy in pediatric Crohn’s disease (CD) remains challenging due to variable drug clearance and response. Identifying pharmacokinetic (PK) and pharmacodynamic (PD) predictors of deep remission could enable precision dosing strategies. The primary aim was to define PK metrics and PD biomarkers associated with deep remission.

Methods

Patients initiating infliximab or adalimumab were prospectively enrolled from four pediatric centers with longitudinal blood and stool biospecimens collected for one year. Deep remission was defined as a combination of weighted pediatric CD activity index (wPCDAI) < 12.5 and Simple Endoscopic Score-CD < 3. Trough concentrations (cTrough) were measured throughout the study. Drug exposure (area under the curve, AUC) and clearance were estimated using drug-specific population PK models and Bayesian estimation using nonlinear mixed-effects modeling (NONMEM).

Results

Deep remission was achieved in 34/70 (48.6%) with no difference in outcomes between biologics. Infliximab cTrough thresholds associated with deep remission were 33 µg/mL (Week 2), 15 µg/mL (Week 6), and 4.7 µg/mL (Month 3) with Week 6 cTrough targets ranging 15–26 µg/mL depending on the outcome of interest. Higher AUC during induction for both infliximab and adalimumab was associated with deep remission, whereas rapid infliximab clearance at various timepoints was inversely associated with deep remission. Baseline predictors of rapid infliximab clearance included older age, low albumin, and elevations in body mass index, C-reactive protein, soluble CD64, and wPCDAI.

Conclusions

We identified PK/PD cut-points associated with deep remission and rapid infliximab clearance, providing actionable metrics to individualize induction dosing and optimize maintenance therapy for children starting anti-TNF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabAdalimumabTumor Necrosis Factor-alphaHumansFemaleMaleChildRemission InductionAdolescentProspective StudiesArea Under CurveBiomarkersBayes Theorem

Substanzen

InfliximabAdalimumabTumor Necrosis Factor-alphaBiomarkers

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, MLC 2010, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
  • University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Esoterix, LabCorp Specialty Lab, Calabasas, CA, USA.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA.

Förderung

  • Division of Diabetes, Endocrinology, and Metabolic Diseases
  • Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Nasr, A., Mizuno, T., Irie, K., Dillman, J. R., Jackson, K., Lynch, K., Horrell, A., Aviles, T., Chun, K., Yang, J., Boyle, B., Hyams, J. S., Noe, J., Denson, L. A., & Minar, P. (2026). Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01685-7

Vancouver

Nasr A, Mizuno T, Irie K, Dillman JR, Jackson K, Lynch K, et al. Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01685-7

BibTeX
@article{Nasr2026,
  author = {Nasr, Alexander and Mizuno, Tomoyuki and Irie, Kei and Dillman, Jonathan R and Jackson, Kimberly and Lynch, Kimberly and Horrell, Alexa and Aviles, Thomas and Chun, Kelly and Yang, Jane and Boyle, Brendan and Hyams, Jeffrey S and Noe, Joshua and Denson, Lee A and Minar, Phillip},
  title = {Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-026-01685-7}
}
Kostenlos starten →